Abdominal Obesity and the Metabolic Syndrome

  • Jean-Pierre Després
  • Isabelle Lemieux
  • Natalie Alméras
Part of the Endocrine Updates book series (ENDO, volume 26)


Metabolic Syndrome Waist Circumference Abdominal Obesity Visceral Adipose Tissue Visceral Obesity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Després JP. Our passive lifestyle, our toxic diet, and the atherogenic/diabetogenic metabolic syndrome: Can we afford to be sedentary and unfit? Circulation 2005;112(4):453–455.PubMedCrossRefGoogle Scholar
  2. [2]
    Zimmet P, Shaw J, Murray S, Sicree R. The diabetes epidemic in full flight: Forecasting the future. Diabetes Voice 2003;48:12–16.Google Scholar
  3. [3]
    Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 1999;42(5):499–518.PubMedCrossRefGoogle Scholar
  4. [4]
    Third-Party Reimbursement for Diabetes Care, Self-Management Education, and Supplies. Diabet Care 2006;29(Suppl 1):S68–S69.Google Scholar
  5. [5]
    He Z, King GL. Microvascular complications of diabetes. Endocrinol Metab Clin North Am 2004;33(1):215–238, xi–xii.PubMedCrossRefGoogle Scholar
  6. [6]
    Grundy SM, Benjamin EJ, Burke GL, et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134–1146.PubMedGoogle Scholar
  7. [7]
    Kaukua J, Turpeinen A, Uusitupa M, Niskanen L. Clustering of cardiovascular risk factors in type 2 diabetes mellitus: Prognostic significance and tracking. Diabetes Obes Metab 2001;3(1):17–23.PubMedCrossRefGoogle Scholar
  8. [8]
    Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men. Diabet Care 2000;23(7):962–968.Google Scholar
  9. [9]
    Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabet Care 2004;27(5):1047–1053.Google Scholar
  10. [10]
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837–853.Google Scholar
  11. [11]
    Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353(25):2643–2653.PubMedCrossRefGoogle Scholar
  12. [12]
    Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210–1214.PubMedGoogle Scholar
  13. [13]
    Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288(21):2709–2716.PubMedCrossRefGoogle Scholar
  14. [14]
    Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabet Care 2001;24(4):683–689.Google Scholar
  15. [15]
    Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279(24):1955–1961.PubMedCrossRefGoogle Scholar
  16. [16]
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112(17):2735–2752.PubMedCrossRefGoogle Scholar
  17. [17]
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37(12):1595–1607.PubMedGoogle Scholar
  18. [18]
    Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat 1967;4:36–41.CrossRefGoogle Scholar
  19. [19]
    Vague J. Sexual differentiation, a factor affecting the forms of obesity. Presse Méd 1947;30:339–340.Google Scholar
  20. [20]
    Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and physical activity of work. Lancet 1953;265(6796):1111–1120; concl.PubMedCrossRefGoogle Scholar
  21. [21]
    Heady JA, Morris JN, Raffle PA. Physique of London busmen; epidemiology of uniforms. Lancet 1956;271(6942):569–570.PubMedGoogle Scholar
  22. [22]
    Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982;54(2):254–260.PubMedCrossRefGoogle Scholar
  23. [23]
    Krotkiewski M, Björntorp P, Sjöström L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983;72:1150–1162.PubMedCrossRefGoogle Scholar
  24. [24]
    Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br Med J 1984;288:1401–1404.Google Scholar
  25. [25]
    Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L. Distribution of adipose tissue and risk of cardiovascular disease and death: A 12 year follow up of participants in the population study of women in Gothenberg, Sweden. Br Med J 1984;289:1257–1261.CrossRefGoogle Scholar
  26. [26]
    Ohlson LO, Larsson B, Svardsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985;34:1055–1058.PubMedGoogle Scholar
  27. [27]
    Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987;36(1):54–59.PubMedCrossRefGoogle Scholar
  28. [28]
    Sjöström L, Kvist H, Cederblad A, Tylen U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. Am J Physiol 1986;250:E736–E745.PubMedGoogle Scholar
  29. [29]
    Peiris AN, Sothmann MS, Hoffmann RG, et al. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 1989;110(11):867–872.PubMedGoogle Scholar
  30. [30]
    Pascot A, Lemieux I, Prud’homme D, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001;42(12):2007–2014.PubMedGoogle Scholar
  31. [31]
    Pouliot MC, Després JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992;41(7):826–834.PubMedGoogle Scholar
  32. [32]
    Tchernof A, Lamarche B, Prud’homme D, et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabet Care 1996;19(6):629–637.Google Scholar
  33. [33]
    Lemieux I, Pascot A, Prud’homme D, et al. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21(6):961–967.PubMedGoogle Scholar
  34. [34]
    Couillard C, Bergeron N, Prud’homme D, et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 1998;47:953–960.PubMedGoogle Scholar
  35. [35]
    Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990;10(4):497–511.PubMedGoogle Scholar
  36. [36]
    Després JP, Lemieux I, Prud’homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 2001;322(7288):716–720.PubMedCrossRefGoogle Scholar
  37. [37]
    Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res 1995;3(Suppl 2):187S–194S.PubMedGoogle Scholar
  38. [38]
    Côté M, Mauriège P, Bergeron J, et al. Adiponectinemia in visceral obesity: Impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005;90(3):1434–1439.PubMedCrossRefGoogle Scholar
  39. [39]
    Goodpaster BH, Krishnaswami S, Harris TB, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005;165(7):777–783.PubMedCrossRefGoogle Scholar
  40. [40]
    Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normalweight individual revisited. Diabetes 1998;47(5):699–713.PubMedGoogle Scholar
  41. [41]
    Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 2000;21(6):697–738.PubMedCrossRefGoogle Scholar
  42. [42]
    Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006;38(1):52–63.PubMedCrossRefGoogle Scholar
  43. [43]
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–2497.Google Scholar
  44. [44]
    Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112(20):3066–3072.PubMedCrossRefGoogle Scholar
  45. [45]
    Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabet Care 2005;28(7):1769–1778.Google Scholar
  46. [46]
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837–1847.PubMedGoogle Scholar
  47. [47]
    Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet 2005;366(9497): 1640–1649.PubMedCrossRefGoogle Scholar
  48. [48]
    Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75(3):473–486.PubMedGoogle Scholar
  49. [49]
    Lemieux S, Prud’homme D, Bouchard C, Tremblay A, Després JP. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr 1993;58(4):463–467.PubMedGoogle Scholar
  50. [50]
    Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73(7):460–468.PubMedCrossRefGoogle Scholar
  51. [51]
    Kuk JL, Lee S, Heymsfield SB, Ross R. Waist circumference and abdominal adipose tissue distribution: Influence of age and sex. Am J Clin Nutr 2005;81(6):1330–1334.PubMedGoogle Scholar
  52. [52]
    Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men? Circulation 2000;102:179–184.PubMedGoogle Scholar
  53. [53]
    Lemieux I, Alméras N, Mauriège P, et al. Prevalence of “hypertriglyceridemic waist” in men who participated in the Quebec Health Survey: Association with atherogenic and diabetogenic metabolic risk factors. Can J Cardiol 2002;18:725–732.PubMedGoogle Scholar
  54. [54]
    Blackburn P, Lamarche B, Couillard C, et al. Postprandial hyperlipidemia: Another correlate of the “hypertriglyceridemic waist” phenotype in men. Atherosclerosis 2003;171(2):327–336.PubMedCrossRefGoogle Scholar
  55. [55]
    St-Pierre J, Lemieux I, Vohl MC, et al. Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. Am J Cardiol 2002;90(1):15–18.PubMedCrossRefGoogle Scholar
  56. [56]
    Després JP, Couillard C, Gagnon J, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: The Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol 2000;20(8):1932–1938.PubMedGoogle Scholar
  57. [57]
    Lovejoy JC, de la Bretonne JA, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: Effects of race. Metabolism 1996;45(9):1119–1124.PubMedCrossRefGoogle Scholar
  58. [58]
    Albu JB, Murphy L, Frager DH, Johnson JA, Pi-Sunyer FX. Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes 1997;46:456–462.PubMedGoogle Scholar
  59. [59]
    Conway JM, Chanetsa FF, Wang P. Intrabdominal adipose tissue and anthropometric surrogates in African American women with upper-and lower-body obesity. Am J Clin Nutr 1997;66:1345–1351.PubMedGoogle Scholar
  60. [60]
    Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363(9403):157–163.Google Scholar
  61. [61]
    Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005;366(9491):1059–1062.PubMedCrossRefGoogle Scholar
  62. [62]
    Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003;361(9374):2005–2016.PubMedCrossRefGoogle Scholar
  63. [63]
    Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597–2604.PubMedCrossRefGoogle Scholar
  64. [64]
    Després JP, Lemieux I, Robins SJ. Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs 2004;64(19):2177–2198.PubMedCrossRefGoogle Scholar
  65. [65]
    Manninen V, Tenkanen L, Koshinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 1992;85:37–45.PubMedGoogle Scholar
  66. [66]
    Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165(10):1154–1160.PubMedCrossRefGoogle Scholar
  67. [67]
    Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343–1350.PubMedCrossRefGoogle Scholar
  68. [68]
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403.PubMedCrossRefGoogle Scholar
  69. [69]
    Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167–172.PubMedCrossRefGoogle Scholar
  70. [70]
    James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356(9248):2119–2125.PubMedCrossRefGoogle Scholar
  71. [71]
    Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabet Care 2004;27(1):155–161.Google Scholar
  72. [72]
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365(9468):1389–1397.PubMedCrossRefGoogle Scholar
  73. [73]
    Després JP, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353(20):2121–2134.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Jean-Pierre Després
    • 1
    • 2
  • Isabelle Lemieux
    • 1
  • Natalie Alméras
    • 3
  1. 1.Québec Heart Institute, Hôpital Laval Research CenterHôpital LavalQuébecCanada
  2. 2.Department of Social and Preventive MedicineUniversité LavalQuébecCanada
  3. 3.Hôpital Laval Research CenterHôpital LavalQuébecCanada

Personalised recommendations